References

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001.

2. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104(22):2746-53.

3. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime Risk for Developing Congestive Heart Failure. Circulation 2002 ; 106:3068-72.

4. Loscalzo J, Creager MA, Dzau VJ, editors. Vascular Medicine. A textbook of Vascular Biology and Diseases. Boston, MA: Little Brown and Co.; 1992.

5. Duthie GG, Arthur JR, James WPT. Effects of smoking and vitamin E on blood antioxidant status. Am J Clin Nutr 1991; 53:S1061-63.

6. Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999; 282(21):2012-8.

7. Stampfer MJ, Hu Fb, Manson Je, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. New England Journal of Medicine 2000; 343(N1):16-22.

8. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.

9. The Panel on Dietary Antioxidants and Related Compounds, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC: National Academy Press; 2000.

10. Ternay A, Sorokin V. Redox, radicals and antioxidants. In: Baskin SI, Salem H, editors. Oxidants, Antioxidants, and Free Radicals. Washington, DC: Taylor and Francis; 1997.

11. Krzanowski JJ. Oxidants, antioxidants and cardiovascular disease. J Fla Med Assoc 1991; 78(7):435-8.

12. Duthie G, Bellizzi MC. Effects of antioxidants on vascular health. Br Med Bull 1999; 55(3):568-77.

13. Jha P, Flather M, Lonn E, et al. The antioxidant vitamins and cardiovascular disease: a critical review of epidemiologic and clinical trial data. Ann Intern Med 1995; 123:860-72.

14. Diplock AT. Antioxidant nutrients and disease prevention. Am J Clin Nutr 1991; 53:S189-93.

15. Hennekens CH , Gaziano J.M. Antioxidants and heart disease: Epidemiology and clinical evidence. Clin Cardiol 1993; 16(4 Suppl):I10-I15.

16. Maxwell S. Antioxidant vitamin supplements. Update of their potential benefits and possible risks. Drug Safety 1999; 21(4):253-66.

17. Clifton PM. Antioxidant vitamins and coronary heart disease risk. Curr Opin Lipidology 1995; 6(1):20-4.

18. Asplund K. Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review. J Intern Med 2002; 251(5):372-92.

19. Tribble DL. Antioxidant consumption and risk of coronary heart disease: Emphasis on vitamin C, vitamin E, and beta-carotene: A statement for healthcare professionals from the American Heart Association. Circulation 1999; 99(4):591-5.

20. German JB, Traber MG. Nutrients and Oxidation: Actions, Transport, and Metabolism of Dietary Antioxidants. In: Rucker RB, Suttie JW, McCormick DB, et al, editors. Handbook of Vitamins. 3rd ed. ed. New York, NY: Marcel Dekker; 2001.

21. Ervin RB, Wright JD, Kennedy-Stephenson J. Use of dietary supplements in the United States, 1988-94. Vital Health Stat 11 1999; (244):i-iii, 1-14.

22. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey . JAMA 2002; 287(3):337-44.

23. Conner M, Kirk SF, Cade JE, et al. Why do women use dietary supplements? The use of the theory of planned behaviour to explore beliefs about their use. Soc Sci Med 2001; 52(4):621-33.

24. McKenzie J, Keller HH. Vitamin-mineral supplementation and use of herbal preparations among community-living older adults. Can J Public Health 2001; 92(4):286-90.

25. McGinnis LS. Alternative therapies, 1990. An overview. Cancer 1991; 67(6 Suppl):1788-92.

26. Frank E, Bendich A, Denniston M. Use of vitamin-mineral supplements by female physicians in the United States. Am J Clin Nutr 2000; 72(4):969-75.

27. Krauss RM, Eckel RH, Howard B, et al. AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000; 102(18): 2284-99.

28. Key TJ, Thorogood M, Appleby PN, et al. Dietary habits and mortality in 11,000 vegetarians and health conscious people: results of a 17 year follow up. BMJ 1996; 313(7060):775-9.

29. de Lorgeril M, Salen P, Martin J-C, et al. Mediterranean diet traditional risk factors and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99:779-85.

30. Trichopoulou A, Vasilopoulou E, Lagiou A. Mediterranean diet and coronary heart disease: are antioxidants critical? Nutr Rev 1999; 57(8):253-5.

31. Strandhagen E, Hansson PO, Bosaeus I, et al. High fruit intake may reduce mortality among middle-aged and elderly men. The Study of Men Born in 1913. Eur J Clin Nutr 2000; 54(4):337-41.

32. Todd S, Woodward M, Tunstall-Pedoe H, et al. Dietary antioxidant vitamins and fiber in the etiology of cardiovascular disease and all-causes mortality: Results from the Scottish Heart Health Study. Am J Epidemiol 1999; 150(10):1073-80.

33. Bolton-Smith C, Woodard M, Tunstall-Pedoe H. Dietary intake by food frequency questionnaire and odds ratios for coronary heart disease risk. II. The antioxidant vitamins and fiber. Eur J Clin Nutr 1992; 46:85-93.

34. Gramenzi A, Gentile A, Fasoli M, et al. Association between certain foods and risk of acute myocardial infarction in women. BMJ 1990; 300(6727):771-3.

35. Law MR, Morris JK. By how much does fruit and vegetable consumption reduce the risk of ishaemic heart disease. Eur J Clin Nutr 1998; 52:549-56.

36. Keli SO, Hertog MG, Feskens EJ, et al. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. Arch Intern Med 1996; 156(6):637-42.

37. Singh RB, Gosh S, Niaz MA, et al. Dietary intake, plasma levels of antioxidant vitamins, and oxidative stress in relation to coronary artery disease in elderly subjects. Am J Cardiol 1995; 76:1233-38.

38. Knekt P, Reunanen A, Jarvinen R, et al. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol 1994; 139(12):1180-9.

39. Gey KF, Moser UK, Jordan P, et al. Increased risk of cardiovascular disease at suboptimal plasma concentrations of essential antioxidants: an epidemiological update with special attention to carotene and vitamin C. Am J Clin Nutr 1993; 57(5 Suppl):787S-97S.

40. Gale C, Ashurst H, Powers H, et al. Antioxidant vitamin status and carotid atherosclerosis in the elderly. Am J Clin Nutr 2001; 74(3):402-8.

41. Kritchevsky SB, Shimakawa T, Tell GS, et al. Dietary antioxidants and carotid artery wall thickness. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995; 92(8):2142-50.

42. Ascherio A, Rimm EB, Hernan MA, et al. Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States. Ann Intern Med 1999; 130(12):963-70.

43. Yochum LA, Folsom AR, Kushi LH. Intake of antioxidant vitamins and risk of death from stroke in postmenopausal women. Am J Clin Nutr 2000; 72(2):476.

44. Kushi LH, Folsom AR, Prineas RJ, et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996; 334:1156-62.

45. Hendler SS, Rovik D, editors. PDR for Nutritional Supplements. Montvale, NJ: Medical Economics Company; 2001.

46. Trout DL. Vitamin C and cardiovascular risk factors. Am J Clin Nutr 1991; 53:322S-5S.

47. Gey KF. Vitamins E plus C and interacting conutrients required for optimal health. A critical and constructive review of epidemiology and supplementation data regarding cardiovascular disease and cancer. Biofactors 1998; 7(1-2):113-74.

48. Niki E. Action of ascorbic acid as a scavenger of active and stable oxygen radicals. Am J Clin Nutr 1991; 54:S1119-24.

49. Baskin SI, Salem H, editors. Oxidants, Antioxidants and Free Radicals. Washington, DC: Taylor and Francis; 1997.

50. Block G, Levine M. Vitamin C: a new look. Ann Intern Med 1991; 114:909-10.

51. Gey KF, Stahelin HB, Eichholzer M. Poor plasma status of carotene and vitamin C is associated with higher mortality from ischemic heart disease and stroke: Basel Prospective Study. Clin Investig 1993; 71(1):3-6.

52. Ginter E. Decline in coronary mortality in United States and vitamin C. Am J Clin Nutr 1979; 32:511-2.

53. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiol 1992; 3:194-202.

54. Maxwell SR, Lip GY. Free radicals and antioxidants in cardiovascular disease. Br J Clin Pharmacol 1997; 44(4):307-17.

55. Mosca L, Rubenfire M, Mandel C, et al. Antioxidant nutrient supplementation reduces the susceptibility of low density lipoprotein to oxidation in patients with coronary artery disease. J Am Coll Cardiol 1997; 30(2):392-9.

56. Vogel R. Cholesterol lowering and endothelial function . Am J Med 1999; 107(5):479-87.

57. Chow C. Vitamin E. In: Rucker RB, Suttie JW, McCormick DB, et al, editors. Handbook of Vitamins. Basel, Switzerland: Marcel Dekker; 2001.

58. Iuliano L, Micheletta F, Maranghi M, et al. Bioavailability of vitamin E as function of food intake in healthy subjects: effects on plasma peroxide-scavenging activity and cholesterol-oxidation products. Arterioscler Thromb Vasc Biol 2001; 21(10):E34-7.

59. Murphy SP, Subar AF, Block G. Vitamin E intakes and sources in the United States. American Journal of Clinical Nutrition 1990; v52(n2):361(7).

60. Pryor W. Vitamin E and heart disease: Basic science to clinical intervention trials. Free Radic Biol Med 2000; 28(1):141-64.

61. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1450-56.

62. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary heart disease in women. N Engl J Med 1993; 328:1444-49.

63. Pruthi S, Allison T, Hensrud D. Vitamin E supplementation in the prevention of coronary heart disease. Mayo Clin Proc 2001; 76(11):1131-6.

64. Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database Syst Rev 2000; (2):CD000987.

65. Kleijnen J, Knipschild P, ter Riet G. Vitamin E and cardiovascular disease. Eur J Clin Pharmacol 1989; 37(6):541-4.

66. Gey KF, Puska P, Jordan P, et al. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991; 53:S326-34.

67. Giugliano D. Dietary antioxidants for cardiovascular prevention. Nutr Metab Cardiovasc Dis 2000; 10(1):38-44.

68. Upston JM, Terentis AC, Stocker R. Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. FASEB J 1999; 13:977-94.

69. Keaney JF, Frei B. Antioxidant protection of low density lipoprotein and its role in the prevention of atherosclerotic vascular disease. In: Frei B, editor. Natural antioxidants in human health and disease. San Diego, CA: Academic Press; 1994. p. 303-51.

70. Kristenson M , Zieden B, Kucinskiene Z, et al. Antioxidant state and mortality form coronary heart disease in Lithuanian and Swedish men: concomitant cross sectional study of men aged 50. BMJ 1997; 314:629-33.

71. Street DA, Comstock GW, Salkeld RM, et al. Serum antioxidants and myocardial infarction. Are low levels of carotenoids and alpha-tocopherol risk factors for myocardial infarction? Circulation 1994; 90(3):1154-61.

72. Suzukawa M, Ayaori M, Shige H, et al. Effect of supplementation with vitamin E on LDL oxidizability and prevention of atherosclerosis. Biofactors 1998; 7(1-2):51-4.

73. Steiner M. Vitamin E: More than an antioxidant. Clin Cardiol 1993; 16(4 Suppl):I16-I18.

74. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001; 20(6):591-8.

75. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996; 42(3):333-7.

76. Watts GF, Castelluccio C, Rice-Evans C, et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993; 46(11):1055-7.

77. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: A double-blind, placebo-controlled study. J Clin Pharmacol 1993; 33(3):226-9.

78. Palomaki A, Malminiemi K, Solakivi T, et al. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. J Lipid Res 1998; 39(7):1430-7.

79. Bargossi AM, Grossi G, Fiorella PL, et al. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med 1994; 15 Suppl:s187-93.

80. Singh RB, Niaz MA, Rastogi V, et al. Coenzyme Q in cardiovascular disease. J Assoc Physicians India 1998; 46(3):299-306.

81. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A 1985; 82(3):901-4.

82. Mortensen SA . Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clin Investig 1993; 71(Suppl 8):S116-23.

83. Crestanello JA, Kamelgard J, Lingle DM, et al. Elucidation of a tripartite mechanism underlying the improvementin cardiac tolerance to ischemia by coenzyme Q10 pretreatment. J Thorac Cardiovasc Surg 1996; 111(2):443-50.

84. Thomas SR, Neuzil J, Stocker R. Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis? Mol Aspects Med 1997; 18 Suppl:S85-103.

85. Hanaki Y, Sugiyama S, Ozawa T, et al. Co-enzyme Q10 and coronary artery disease. Clin Invest 1993; 71:S112-15.

86. Jameson S. Statistical data support prediction of death within 6 months on low levels of coenzyme Q10 and other entities. Clin Investig 1993; 71(8 Suppl):S137-9.

87. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q-10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 1997; 18(Supp):s159-68.

88. Bendich A. Safety issues regarding the use of vitamin supplements. Ann N Y Acad Sci 1992; 669:300-10; discussion 311-2.

89. Bendich A, Machlin LJ. Safety of oral intake of vitamin E. Am J Clin Nutr 1988; 48:612-9.

90. Lockwood K, Moesgaard S, Hanioka T, et al. Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 1994; 15 Suppl:s231-40.

91. Hansten PD, Horn JR. Drug Interactions Analysis and Management. Vancouver, WA: Applied Therapeutics Inc.; 1997.

92. Leppala JM, Virtamo J, Fogelholm R, et al. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol 2000; 20(1):230-5.

93. Malila N, Virtamo J, Virtanen M, et al. The effect of alpha-tocopherol and beta-carotene supplementation on colorectal adenomas in middle-aged male smokers. Cancer Epidemiol Biomarkers Prev 1999; 8(6):489-93.

94. MRC/BHF Heart Protection Study Collaborative group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:23-33.

95. Jellin JM, Batz F, Hitchens MK, editors. Pharmacist's Letter/Prescriber's Letter Natural Medicines Comprehensive Database. Stockton, CA: Therapeutic Research Facility; 2001.

96. Levine M, Rumsey SC, Daruwala R, et al. Criteria and recommendations for vitamin C intake. JAMA 1999; 281(15):1415-23 .

97. Bendich A, Langseth L. The health effects of vitamin C supplementation: a review. J Am Coll Nutr 1995; 14(2):124-36.

98. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17(1):1-12.

99. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273(5):408-12.

100. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352(9128):609-13.

101. Microsoft Excel for Windows 2000 [computer program]. Redmond, WA: Microsoft Corporation; 2000.

102. Stata Statistical Software: Release 6.0, Version 6.0 [computer program]. College Station, TX: Stata Corporation; 1999.

103. Hedges LV, Olkin I. Statistical methods for meta-analysis. San Diego, CA: Academic Press; 1985.

104. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3):177-88.

105. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50(4):1088-101.

106. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109):629-34.

107. Virtamo J, Rapola JM, Ripatti S, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med 1998; 158(6):668-75.

108. Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349(9067):1715-20.

109. Rapola JM, Virtamo J, Ripatti S, et al. Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris. Heart 1998; 79(5):454-8.

110. Mark SD, Wang W, Fraumeni JF, et al. Do nutritional supplements lower the risk of stroke or hypertension? Epidemiology 1998; 9:9-15.

111. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357(9250):89-95.

112. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3):154-60.

113. Porkkala-Sarataho EK, Nyyssonen MK, Kaikkonen JE, et al. A randomized, single-blind, placebo-controlled trial of the effects of 200 mg alpha -tocopherol on the oxidation resistance of atherogenic lipoproteins. Am J Clin Nutr 1998; 1034-41.

114. Salonen JT, Nyyssonen K, Salonen R, et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: A randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Int Med 2000; 248(5):377-86.

115. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvianza nell'Infarto Miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354(9177):447-55.

116. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347(9004):781-6.

117. Brown BG, Xue-Qiao Z, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345(22):1583-92.

118. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997; 337(6):365-72.

119. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 2000; 356(9237):1213-8.

120. Gillilan RE, Mondell B, Warbasse JR. Quantitative evaluation of vitamin E in the treatment of angina pectoris. Am Heart J 1977; 93(4):444-9.

121. Ness A, Smith GD. Mortality in the CHAOS trial. Cambridge Heart Antioxidant Study. Lancet 1999; 353(9157):1017-8.

122. Singh RB, Niaz MA, Rastogi SS, et al. Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival-3). Am J Cardiol 1996; 77(4):232-6.

123. Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. J Card Fail 1995; 1(2):101-7.

124. Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 2000; 132(8):636-40.

125. Leppala JM, Virtamo J, Fogelholm R, et al. Vitamin E and beta carotene supplementation in high risk for stroke: a subgroup analysis of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Arch Neurol 2000; 57(10):1503-9.

126. Steiner M, Glantz M, Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am J Clin Nutr 1995; 62(6 Suppl):1381S-4S.

127. Tornwall ME, Virtamo J, Haukka JK, et al. Alpha-tocopherol (vitamin E) and beta-carotene supplementation does not affect the risk for large abdominal aortic aneurysm in a controlled trial. Atherosclerosis 2001; 157(1):167-73.

128. Di Somma S, Carati L. Efficacy of coenzyme Q10 in association with conventional therapy in the treatment of heart failure and ischemic heart disease. In: Folkers K, Yamamura Y, editors. Biomedical and Clincal Aspects of Coenzyme Q10. Amsterdam: Elsevier; 1991. p. 257-65.

129. Rapola JM, Virtamo J, Ripatti S, et al. Effects of vitamin E and beta-carotene supplementation on the incidence of major coronary events in men with previous myocardial infarction. Eur Heart 1997; 18(Abstr. Suppl):251.

130. Stollerman GH. Vitamin E, coronary artery disease, and CHAOS. Hosp Pract (Off Ed) 1996; 31(6):21-2.

131. Haeger K. The treatment of peripheral occlusive arterial disease with alpha-tocopherol as compared with vasodilator agents and antiprothrombin (dicumarol). Vasc Dis 1968; 5(4):199-213.

132. Haeger K. Letter: Vitamin E in intermittent claudication. Lancet 1974; 1(7870):1352.

133. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002; 288(19):2432-40.

134. Takamatsu S, Takamatsu M, Satoh K, et al. Effects on health of dietary supplementation with 100 mg d-alpha-tocopheryl acetate, daily for 6 years. J Int Med Res 1995; 23(5):342-57.

135. Kuklinski B, Weissenbacher E, Fahnrich A. Coenzyme Q10 and antioxidants in acute myocardial infarction. Mol Aspects Med 1994; 15 Suppl:s143-7.

136. Sisto T, Paajanen H, Metsa-Ketela T, et al. Pretreatment with antioxidants and allopurinol diminishes cardiac onset events in coronary artery bypass grafting. Ann Thorac Surg 1995; 59(6):1519-23.

137. Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther 1998; 12(4):347-53.

138. Kaikkonen J, Kosonen L, Nyyssonen K, et al. Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercised-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners. Free Radic Res 1998; 13:1528-33.

139. Wen Y, Cooke T, Feely J. The effect of pharmacological supplementation with vitamin C on low-density lipoprotein oxidation. Br J Clin Pharmacol 1997; 44:94-7.

140. Porkkala-Sarataho E, Salonen J.T, Nyyssonen K, et al. Long-term effects of vitamin E, vitamin C, and combined supplementation on urinary 7-hydro-8-oxo-2'-deoxyguanosine, serum cholesterol oxidation products, and oxidation resistance of lipids in nondepleted men. Arterioscler Thromb Vasc Biol 2000; 20(9):2087-93.

141. Raitakari OT, McCredie RJ, Witting P, et al. Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolemic young adults. Free Radic Biol Med 2000a; 28(7):1100-5.

142. Iino K, Abe K, Kariya S, et al. A controlled, double-blind study of dl-alpha-tocopheryl nicotinate (Juvela-Nicotinate) for treatment of symptoms in hypertension and cerebral arteriosclerosis. Jpn Heart J 1977; 18(3):277-83.

143. O'Byrne D, Grundy S, Packer L, et al. Studies of LDL oxidation following alpha-, gamma-, or delta-tocotrienyl acetate supplementation of hypercholesterolemic humans. Free Radic Biol Med 2000; 29(9):834-45.

144. Samman S, Brown AJ, Beltran C, et al. The effect of ascorbic acid on plasma lipids and oxidisability of LDL in male smokers. Eur J Clin Nutr 1997; 51:472-7.

145. Gatto LM, Hallen GK, Brown AJ, et al. Ascorbic acid induces favorable lipoprotein profile in women. J Am Coll Nutr 1996; 15:154-8.

146. Nyyssonen K, Poulsen HE, Hayn M, et al. Effect of supplementation of smoking men with plain or slow release ascorbic acid on lipoprotein oxidation. Eur J Clin Nutr 1997; 51:154-63.

147. Nappo F, De Rosa N, Marfella R, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281(22):2113-8.

148. Lankin VZ, Tikhaze AK, Kaminnaya VI, et al. In vivo intensification of free-radical oxidation of low-density lipoproteins in the plasma of patients with coronary heart disease treated with beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor pravastatin and inhibition of lipid peroxidation with ubiquinone Q10. Bull Exp Biol Med 2000; 129(2):151-4.

149. Singh RB, Niaz MA. Serum concentration of lipoprotein(a) decreases on treatment with hydrosoluble coenzyme Q10 in patients with coronary artery disease: discovery of a new role. Int J Cardiol 1999a; 68(1):23-9.

150. Singh RB, Niaz MA, Rastogi SS, et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens 1999b; 13(3):203-8.

151. Kaikkonen J, Nyyssonen K, Tomasi A, et al. Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study. Free Radic Res 2000; 33(3):329-40.

152. Anderson JW, Gowri MS, Turner J, et al. Antioxidant supplementation effects on low-density lipoprotein oxidation for individuals with type 2 diabetes mellitus. J Am Coll Nutr 1999; 18(5):451-61.

153. Osilesi OD, Trout L, Ogunwole JO, et al. Blood pressure and plasma lipids during ascorbic acid supplementation in borderline hypertensive and normotensive adults. Nutr Res 1991; 11:405-12.

154. Guetta V, Panza JA, Waclawiw MA, et al. Effect of combined 17 beta-estradiol and vitamin E on low-density lipoprotein oxidation in postmenopausal women. Am J Cardiol 1995; 75(17):1274-6.

155. Inal M, Sunal E, Kanbak G, et al. Effects of postmenopausal hormone replacement and alpha-tocopherol on the lipid profiles and antioxidant status. Clin Chim Acta 1997; 268(1-2):21-9.

156. Mensink RP, Houwelingen ACv, Kromhout D, et al. A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Am J Clin Nutr 1999; 69(2):213(1).

157. Reaven PD, Witztum JL. Comparison of supplementation of RRR-alpha-tocopherol and racemic alpha-tocopherol in humans: effects on lipid levels and lipoprotein susceptibility to oxidation. Arterioscl Thromb 1993; 13:601-8.

158. Qureshi AA, Bradlow BA, Brace L, et al. Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids 1995; 30(12):1171-7.

159. Munday JS, James KA, Fray LM, et al. Daily supplementation with aged garlic extract, but not raw garlic, protects low density lipoprotein against in vitro oxidation. Atherosclerosis 1999; 143(2):399-404.

160. Singhal S, Gupta R, Goyle A. Comparison of antioxidant efficacy of vitamin E, vitamin C, vitamin A and fruits in coronary heart disease: a controlled trial. J Assoc Physicians India 2001; 49:327-31.

161. Tsai A, Kelly J, Peng B, et al. Study on the effect of megavitamin E supplementation in man. Am J Clin Nutr 1978; 31:831-7.

162. Dieber-Rotheneder M, Puhl H, Waeg G, et al. Effect of oral supplementation with D-alpha-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J Lipid Res 1991; 32:1325-32.

163. Harats D, Ben-Naim M, Dabach Y, et al. Effect of vitamin C and E supplementation on susceptibility of plasma lipproteins to peroxidation induced by acute smoking. Atherosclerosis 1990; 85:47-54.

164. Meraji S, Ziouzenkova O, Resch U, et al. Enhanced plasma level of lipid peroxidation in Iranians could be improved by antioxidants supplementation. Eur J Clin Nutr 1997; 51(5):318-25.

165. Raitakari O , Adams MR, McCredie RJ, et al. Oral vitamin C and endothelial function in smokers: Short-term improvement, but no sustained beneficial effect. J Am Coll Cardiol 2000b; 35(6):1616-21.

166. Wen Y, Killalea S, Norris LA, et al. Vitamin E supplementation in hyperlipidaemic patients: effect of increasing doses on in vitro and in vivo low-density lipoprotein oxidation. Eur J Clin Invest 1999; 29(12):1027-34.

167. Brown KM, Morrice PC, Duthie GG. Vitamin E supplementation suppresses indexes of lipid peroxidation and platelet counts in blood of smokers and nonsmokers but plasma lipoprotein concentrations remain unchanged. Am J Clin Nutr 1994; 60(3):383-7.

168. De Waart FJ, Moser U, Kok FJ. Vitamin E supplementation in elderly lowers the oxidation rate of linoleic acid in LDL. Atherosclerosis 1997; 133:255-63.

169. DeMaio SJ, King SB3, Lembo NJ, et al. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA). J Am Coll Nutr 1992; 11(1):68-73.

170. Fuller CJ, Chandalia M, Garg A, et al. RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Am J Clin Nutr 1996b; 63(5):753-9.

171. Hoffman RM, Garewal HS. Alpha-tocopherol supplementation for men with existing coronary artery disease: a feasibility study. Prev Med 1999; 29(2):112-8.

172. Jain SK, McVie R, Jaramillo JJ, et al. The effect of modest vitamin E supplementation on lipid peroxidation products and other cardiovascular risk factors in diabetic patients. Lipids 1996; 31 Suppl:S87-90.

173. Jialal I, Fuller CJ, Huet BA. The effect of alpha-tocopherol supplementation on LDL oxidation: a dose response study. Arterioscler Thromb Vasc Biol 1995; 15:190-98.

174. Jialal I, Grundy SM. Effect of dietary supplementation with alpha-tocopherol on the oxidative modification of low density lipoprotein. J Lipid Res 1992; 33:899-906.

175. Jialal I, Grundy SM. Effect of combined supplementation with alpha-tocopherol, ascorbate, and beta carotene on low-density lipoprotein oxidation. Circulation 1993; 88(6):2780-6.

176. McDowell I, Brennan G, McEneny J. The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans. Eur J Clin Invest 1994; 24:759-65.

177. McGavin JK, Mann JI, Skeaff CM, et al. Comparison of a vitamin E-rich diet and supplemental vitamin E on measures of vitamin E status and lipoprotein profile. Eur J Clin Nutr 2001; 55(7):555-61.

178. Mottram P, Shige H, Nestel P. Vitamin E improves arterial compliance in middle-aged men and women. Atherosclerosis 1999; 145(2):399-404.

179. Nyyssonen K , Porkkala E, Salonen R, et al. Increase in oxidation resistance of atherogenic serum lipoproteins followign antioxidant supplementation: a randomized double-blind placebo-controlled trial. Eur J Clin Nutr 1997; 48:633-42.

180. Paolisso G, Gambardella A, Giugliano D, et al. Chronic intake of pharmacological doses of vitamin E might be useful in the therapy of elderly patients with coronary heart disease. Am J Clin Nutr 1995; 61(4):848-52.

181. Schafer L, Thorling EB. Lipid peroxidation and antioxidant supplementation in old age. Scand J Clin Lab Invest 1990; 50(1):69-75.

182. Stampfer MJ, Willett W, Castelli WP, et al. Effect of vitamin E on lipids. Am J Clin Pathol 1983; 79(6):714-6.

183. Tomeo AC, Geller M, Watkins TR, et al. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Lipids 1995; 30(12):1179-83.

184. de Lorgeril M, Boissonnat P, Salen P, et al. The beneficial effect of dietary antioxidant supplementation on platelet aggregation and cyclosporine treatment in heart transplant recipients. Transplantation 1994; 58(2):193-5.

185. Okamura T, Sunamori M, Amano J, et al. Significant myocardial protection by coenzyme Q10 in coronary bypass surgery. J Mol Cell Cardiol 1983; 15(Suppl 1):276.

186. Tanaka J, Tominaga R, Yoshitoshi M, et al. Coenzyme Q10: the prophylactic effect on low cardiac output following cardiac valve replacement. Ann Thorac Surg 1982; 33(2):145-51.

187. Judy WV, Stogsdill WW, Folkers K. Myocardial preservation by therapy with coenzyme Q10 during heart surgery. Clin Investig 1993; 71(8 Suppl):S155-61.

188. Chen YF, Lin YT, Wu SC. Effectiveness of coenzyme Q10 on myocardial preservation during hypothermic cardioplegic arrest. J Thorac Cardiovasc Surg 1994; 107(1):242-7.

189. Chello M, Mastroroberto P, Romano R, et al. Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting. Ann Thorac Surg 1994; 58(5):1427-32.

190. Taggart DP, Jenkins M, Hooper J, et al. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations. Ann Thorac Surg 1996; 61(3):829-33.

191. Chello M, Mastroroberto P, Romano R, et al. Protection by coenzyme Q10 of tissue reperfusion injury during abdominal aortic cross-clamping. J Cardiovasc Surg (Torino) 1996; 37(3):229-35.

192. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig 1993; 71(supp):s134-36.

193. Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999; 33(6):1549-52.

194. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288(1):49-57.

195. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-97.